CJC-1295-related drug substances
FDA distinguishes multiple forms—including free base, acetate, CJC-1295 DAC, DAC acetate, and DAC trifluoroacetate—and its 2024 review did not identify an FDA-approved CJC-1295 drug product.
Current sourceCJC-1295
Small human pharmacology studies do not establish the online body-composition claims
CJC-1295 refers to related growth hormone-releasing hormone analog forms, including a drug-affinity-complex form designed to bind albumin. Small, short studies in healthy adults showed prolonged changes in growth hormone and IGF-I biomarkers. They did not establish treatment of obesity, muscle gain, injury recovery, anti-aging, or long-term safety. FDA has identified limited clinical data and serious adverse events associated with CJC-1295 in its compounding assessment.
Editorial status
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .
It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
CJC-1295 in compounding
FDA identifies potential immunogenicity and peptide-characterization concerns, limited clinical data, and serious adverse events including increased heart rate and systemic vasodilatory reaction.
Current sourceCJC-1295 in sport
CJC-1295 is named among prohibited growth hormone-releasing factors on WADA's 2026 Prohibited List.
Current sourceClaim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
CJC-1295 DAC produced sustained GH and IGF-I biomarker increases in small studies of healthy adults.
- Population
- Healthy adults aged 21 to 61 in two randomized, placebo-controlled, ascending-dose studies lasting 28 or 49 days.
- Finding
- The study reported dose-dependent increases in mean growth hormone and IGF-I concentrations and an estimated CJC-1295 half-life of 5.8 to 8.1 days.
- Limits
- Biomarker changes in healthy volunteers over several weeks do not establish improved body composition, recovery, healthy aging, or clinical benefit, and do not define long-term safety.
Growth hormone pulsatility persisted after a single CJC-1295 injection in a small mechanistic study.
- Population
- Healthy men aged 20 to 40 assessed before and one week after a single injection.
- Finding
- Overnight sampling found increased trough and mean GH secretion and increased IGF-I while secretory pulse frequency and magnitude were preserved.
- Limits
- This before-and-after endocrine study measured biomarkers, not patient-centered benefits or safety across repeated, long-term, or combined use.
A small proteomic study found serum protein changes after CJC-1295 exposure.
- Population
- Eleven healthy young adult men, comparing serum before and one week after injection.
- Finding
- The researchers explored candidate serum markers associated with activation of the GH/IGF-I axis.
- Limits
- Exploratory biomarker findings in 11 participants do not demonstrate muscle gain, fat loss, recovery, longevity, or a favorable risk-benefit profile.
FDA's compounding review distinguishes CJC-1295 forms that online descriptions may blur together.
- Population
- FDA review of CJC-1295-related bulk substances nominated for compounding.
- Finding
- FDA separately evaluated CJC-1295 without DAC and several DAC forms and concluded available information was too limited to support the proposed compounding uses.
- Limits
- A regulatory review does not quantify the risk of a specific vial, and findings from one chemical form should not automatically be transferred to another.
What this evidence does not answer
- No adequate randomized outcomes trial establishes CJC-1295 for fat loss, muscle gain, injury recovery, sleep, anti-aging, or wellness.
- The human studies are small, short, and primarily measure GH, IGF-I, pharmacokinetics, or exploratory biomarkers in healthy adults.
- Long-term cardiovascular, metabolic, cancer-related, pituitary, immunogenicity, and reproductive risks are not characterized.
- Evidence for CJC-1295 DAC cannot automatically be applied to non-DAC products, combinations with other peptides, or products of uncertain identity.
Useful information to organize between visits
- Exact label name and whether the product specifies DAC, no DAC, salt form, sequence, and concentration
- Seller or dispensing pharmacy, lot number, storage history, labeled ingredients, and packaging photographs
- Date and route of any exposure, without using this page to construct a regimen
- Symptoms with onset, severity, duration, heart-rate observations if already measured, and any urgent care
- Other hormones, peptides, supplements, and medicines that could alter the GH/IGF-I axis or obscure attribution
Questions to bring to a clinician or pharmacist
- 1.Which chemical form does this product claim to contain, and can its identity or quality actually be verified?
- 2.Could changing the GH/IGF-I axis pose added risk given my health history, medicines, or laboratory findings?
- 3.What symptoms after exposure should prompt urgent evaluation or adverse-event reporting?
- 4.What evidence-based alternatives address the outcome being sought without relying on an unapproved peptide?
Primary sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · Published Updated 2026 · Accessed July 12, 2026
- FDA Briefing Document: CJC-1295-related bulk drug substancesU.S. Food and Drug Administration · Published 2024 · Accessed July 12, 2026
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adultsJournal of Clinical Endocrinology & Metabolism via PubMed · Published 2006 · Accessed July 12, 2026
- Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295Journal of Clinical Endocrinology & Metabolism via PubMed · Published 2006 · Accessed July 12, 2026
- Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changesGrowth Hormone & IGF Research via PubMed · Published 2009 · Accessed July 12, 2026
- 2026 Prohibited ListWorld Anti-Doping Agency · Published 2026 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free